{"id":35879,"date":"2026-07-28T16:12:00","date_gmt":"2026-07-28T14:12:00","guid":{"rendered":"https:\/\/askme.it\/insights\/approved-email-in-pharma-the-loop-worth-30-in-prescriptions\/"},"modified":"2026-05-28T17:55:00","modified_gmt":"2026-05-28T15:55:00","slug":"approved-email-in-pharma-the-loop-worth-30-in-prescriptions","status":"publish","type":"insights","link":"https:\/\/askme.it\/en\/insights\/approved-email-in-pharma-the-loop-worth-30-in-prescriptions\/","title":{"rendered":"Approved Email in pharma: the loop worth 30% in prescriptions"},"content":{"rendered":"
\n

The 2025 Veeva HCP 360 Trends Report, built on operational data from over 600 million HCP interactions by 80% of global biopharma field teams, contains a finding that reconfigures the way pharmaceutical companies should think about their email investment. Content-driven engagement more than doubles new treatment starts, but content is actually used in fewer than half of HCP meetings. Synchronization between an F2F visit and a digital exposure within ten days increases the probability of prescription by 30%, but 65% of engagements remain unsynchronized. Almost 80% of content approved by Medical-Legal-Regulatory review is rarely or never used by the sales force.<\/p>\n

Pharma Approved Email \u2014 the MLR-approved email that the representative sends following a visit or as an independent follow-up channel \u2014 is the single tool that directly attacks this dysfunction. Veeva reports over one hundred biopharma companies on the Approved Email product, with open rates ranging from 40% to 90% depending on integration and channel. Salesforce brought Agentforce Life Sciences to general availability on October 11, 2025 with an orchestration layer built on top of Marketing Cloud Next. Indegene launched NEXT MLR Review Automation in 2025, an agentic system that cuts the review cycle by 30% to 50%. The lever is available. The process remains to be built.<\/p>\n<\/section>\n

\n

What Approved Email actually does<\/h2>\n

The basic architecture of pharma Approved Email is a library of templates that have passed the MLR \u2014 Medical, Legal, Regulatory \u2014 review cycle and that the representative can activate with personalizations limited to the fields foreseen by the approval. The representative does not write a free email to the physician: they select an approved template, choose the allowed variants \u2014 greeting, reference to the previous visit, selectable attachments from an authorized pool \u2014 and send. The system tracks opens, clicks, reading time, and feeds the data back into the CRM. For the physician the email is an authoritative scientific follow-up; for the company it is a measurable engagement tool; for the regulator it is traceable communication.<\/p>\n

Next-generation platforms have added two capabilities on top of this base layer that are relevant for 2026. The first is contextual post-visit suggestion: the system, upon closure of the call report, proposes to the representative one or two approved templates pertinent to the content of the recorded visit, accelerating the email trigger. The second is content modularization: instead of approving each email through MLR as a monolithic object, companies approve content blocks \u2014 claims, evidence, images, disclaimers \u2014 that compose dynamically inside an approved shell. Indegene has published a case study with a top-10 pharma in which the AI deconstruction of existing content allowed the tagging of over 200,000 pages in 30 countries and 18 languages, with an 85% reduction in tagging effort.<\/p>\n<\/section>\n

\n

Pharma open rates: reading the numbers correctly<\/h2>\n

The open rates cited in Veeva materials and biopharma case studies \u2014 40% baseline, 60% on mature deployments, up to 90% on the Engage Meeting channel where content is pulled on demand by the HCP \u2014 should be read with attention to their context. Pharma email is an opt-in channel, in which the physician has explicitly consented to receive promotional communications from a specific company. The 40% baseline is not comparable to the 20% of consumer B2B marketing automation, where the channel is push and opt-in is less selective. The 90% Engage Meeting figure is not general: it applies to content that the physician has actively requested from the representative during a conversation and receives as a specific follow-up.<\/p>\n

The realistic value point for an Italian pharmaceutical company in 2026 is a baseline between 35% and 45% on rep-triggered emails with MLR-approved templates, a threshold above 60% only for content that has been specifically requested, and a significant drop for generalist newsletter-type emails. The metric that weighs more than the single open rate is the sync rate: if 65% of HCP interactions are not synchronized \u2014 F2F visit followed by email within ten days \u2014 the largest value lever is not raising the open rate by five points, it is bringing the unsynchronized 65% below 40%. The difference is worth, according to Veeva, 30% of Rx.<\/p>\n<\/section>\n

\n

MLR is the real bottleneck<\/h2>\n

The 2025 Vodori and Indegene surveys measure MLR review cycles between 50 and 60 days per asset in large U.S. pharma, with a European average of around 20 days and 1.3 review cycles per asset. Pharma content production grew 7% globally and 29% in the United States in 2023, while review capacity remained substantially unchanged. The combination \u2014 more volume to approve with unchanged capacity \u2014 forces companies into suboptimal operational choices: producing generic reusable content, reducing the frequency of new variant launches, accumulating backlog. It is the structural dynamic that produces the Veeva data of 77-80% of approved content unused: you approve what you can manage to approve, not what would be needed.<\/p>\n

AI on MLR review attacks this bottleneck from three simultaneous angles. Veeva PromoMats introduced the agentic Quick Check in 2025, an automatic pre-compliance check that intercepts the most common errors before entering human review. BCG quantified in its own 2025 analysis a 30-50% reduction in the cost of content generation thanks to GenAI, with a documented case of a 75% reduction in campaign time-to-launch in a large pharma. Indegene NEXT MLR Automation reports a cycle reduction between 30% and 50%. For an Italian company planning a series of launches in 2026, the cumulative gain is not marginal: moving from 1.3 review cycles to 1.0 or accelerating the time-to-market of an asset by a week changes the overall commercial cadence.<\/p>\n<\/section>\n

\n

The Italian constraint: opt-in, Farmindustria, Sunshine Act<\/h2>\n

For a pharmaceutical company operating in Italy, the design of Approved Email in 2026 must be built on top of three constraints that U.S. platforms do not solve natively. The first is the explicit GDPR consent of the HCP for promotional electronic communications, with the possibility of tracked revocation and a one-click opt-out mechanism in every send. Rep-triggered does not replace consent: the HCP must have consented to receive emails from that specific company, and the template sent must fall within the declared scope of consent. The second is the Farmindustria Code of Conduct of February 21, 2025, which requires the classification of every content as promotional or non-promotional, the complete audit trail of delivery, and annual ACCREDIA certification of scientific information procedures.<\/p>\n

The third is Sanit\u00e0 Trasparente (Italian Sunshine Act), operational since 2025, which mandates public disclosure to the Ministry of Health of transfers of value to HCPs above thresholds of 100 euros per single event and 1,000 euros per year. An Approved Email inviting to a sponsored event or carrying material of commercial value falls within Sunshine Act traceability. The winning model for 2026 Italy is not that of the behavioral drip campaign that B2B SaaS companies use in the United States: it is the catalog of MLR-approved templates that the representative “activates” as a follow-up to their own visit, with AI personalization on the fields foreseen by the approval but always rep-in-the-loop. The +30% in Rx exists. It is won through process design, not through platform licensing.<\/p>\n<\/section>\n","protected":false},"excerpt":{"rendered":"

Veeva HCP 360 2025: syncing an Approved Email within ten days of a visit increases the probability of prescription by 30%. 65% of HCP interactions are not synchronized. MLR review remains at 20 days in Europe and 50-60 in the United States. Indegene NEXT MLR Automation cuts the cycle by 30-50%.<\/p>\n","protected":false},"featured_media":35881,"menu_order":0,"template":"","insights_category":[968],"insights_tags":[912,914,890,913,874],"class_list":["post-35879","insights","type-insights","status-publish","has-post-thumbnail","hentry","insights_category-ai-and-pharma","insights_tags-approved-email","insights_tags-mlr-review","insights_tags-modular-content","insights_tags-rep-triggered","insights_tags-veeva"],"acf":[],"_links":{"self":[{"href":"https:\/\/askme.it\/en\/wp-json\/wp\/v2\/insights\/35879","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/askme.it\/en\/wp-json\/wp\/v2\/insights"}],"about":[{"href":"https:\/\/askme.it\/en\/wp-json\/wp\/v2\/types\/insights"}],"version-history":[{"count":1,"href":"https:\/\/askme.it\/en\/wp-json\/wp\/v2\/insights\/35879\/revisions"}],"predecessor-version":[{"id":35880,"href":"https:\/\/askme.it\/en\/wp-json\/wp\/v2\/insights\/35879\/revisions\/35880"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/askme.it\/en\/wp-json\/wp\/v2\/media\/35881"}],"wp:attachment":[{"href":"https:\/\/askme.it\/en\/wp-json\/wp\/v2\/media?parent=35879"}],"wp:term":[{"taxonomy":"insights_category","embeddable":true,"href":"https:\/\/askme.it\/en\/wp-json\/wp\/v2\/insights_category?post=35879"},{"taxonomy":"insights_tags","embeddable":true,"href":"https:\/\/askme.it\/en\/wp-json\/wp\/v2\/insights_tags?post=35879"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}